Why the study?
The increasing use of successful chemotherapeutic agents has led to an increasing incidence of cardiovascular complications, primarily cardiotoxicity manifested as left ventricular systolic dysfunction.
What are the commonly used chemotherapeutic agents that cause cardiotoxicity, and what are the current treatment options and evidence gaps?
What are the commonly used chemotherapeutic agents that cause cardiotoxicity, and what are the current treatment options and evidence gaps?
This review highlights the growing issue of chemotherapy-induced cardiotoxicity and summarizes current knowledge on causative agents and management strategies.
May warrant routine CV monitoring during chemotherapy; leaves optimal prevention strategies open for prospective trials.
Rapid advancements in oncological treatments over the past few decades have led to a significant improvement in cancer outcomes. Chemotherapeutic agents play a pivotal role in cancer treatment, with almost one-third of patients receiving them during their cancer treatment in the United Kingdom. The success of chemotherapeutic drugs has, however, resulted in an increasing incidence of cardiovascular side effects and complications. The most common cardiac manifestation is the development of cardiotoxicity, defined as the development of left ventricular systolic dysfunction, after treatment. This article provides an up-to-date review of the commonly used chemotherapeutic agents that cause cardiotoxicity and discusses current treatment options and evidence gaps.
No takes yet. Share an insight, caveat, or question.
Bannister et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: